IPHC is then administered as part of the operative procedure. This permits direct contact of very high cancer drug concentrations with remaining cancer cells. Heating is used to increase the effectiveness of this interaction. Five-year data show patients undergoing this treatment live longer and have a better quality of life. IPHC is now offered at our medical center as a standard of care.
Ongoing research is a commitment to improvement in patient care and safety.
Our goal of the partnership with IDT is to standardize the perfusion delivery system. This will permit wider application of this treatment modality and facilitate further clinical research. The medical school and IDT also announced they have entered into a research agreement to utilize the ThermoChem-HT equipment and associated disposables in a series of studies designed to evaluate and further improve the method of heated perfusion of chemotherapy drugs. This follows the FDA's approval to initiate study for advanced gastrointestinal cancer utilizing Loggie's procedure and the ThermoChem-HT and disposables. The agreement also allows Medical Center physicians to use this equipment in developing similar uses that may lead to additional FDA 510K approvals for other types of cancers.